Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

Authors

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators

Journal

N Engl J Med

Volume

372

Issue

16

Pages

1500-9

Publication year

2015

Suggested citation

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1500-9.

DOI

10.1056/NEJMoa1500858

PMID

25773607

Header sites

Search form

Main menu

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

Nav